release is selective and depends on the stimulus applied. In this respect AF-2 mimics, at least in part, the actions of both glucocorticoids and lipocortin-1.
Introduction
Uteroglobin and lipocortin-12 belong to a family of structurally related proteins referred to as annexins or lipocortins which are calcium-binding proteins. 3-s Lipocortins are glucocorticoid-inducible proteins which, by inhibiting phospholipase A2 (PLA2), are believed to be involved in the suppression of prostaglandin and leukotriene synthesis associated with some aspects of the anti-inflammatory activity of corticosteroids. 6 Recently nonapeptide fragments of uteroglobin and lipocortin-1, named antiflammins,7 have been shown to inhibit PLA2 in vitro and to possess anti-inflammatory activity in vivo. [7] [8] [9] One of these nonapeptides, antiflammin-2 (AF-2, HDMNKVLDL) corresponds to the amino acid residues 246-254 of lipocortin-l.7 However, conflicting results have been reported concerning the biological activity of AF-2. The peptide has been shown to inhibit carrageenan-induced rat paw oedema, 9 porcine pancreatic PLA27 and human polymorphonuclear leucocyte PLA 2 (Fig. 1) . The peak response was observed 2 min after the challenge (289 -k 6 ng min-; n 4), thereafter the TXB 2 release rapidly declined to a low level after 10 min (16 10 ng min-1; n-4).
When the lung was infused with AF-2 the LTC4-induced TXB2 release was greatly reduced throughout the time course of the response (Fig. 1) . The peak response was reduced by the peptide in a concentration-related fashion as inhibition of 36%, 54% and 61% were induced by 10, 30 and 100 nM infusion of AF-2.
In contrast, neither the time course nor the peak response of the TXB 2 release induced by histamine (5 #g) or bradykinin (5/4g) in normal lungs were aEected by infusion of AF-2 up to 100 nM. In fact, the peak of TXB2 release from lungs challenged with histamine (75_-t-2.8ngmin-l", n-4) was unat:fected by 100nM AF-2 infusion (82-F 2 ng min-l"n, --4), as the peak of TXB 2 release from lungs challenged with bradykinin (78-f- 13 ng min-l" n 4)
However the antigen-induced release of TXB 2 from sensitized lungs was reduced by 100 nM AF-2 ( Fig. 2A) . The peak release, which was ten-fold higher than that obtained with other stimuli (635 39 ng min-l"n, -6), was significantly inhibited by 32% (431 -t-8.7ngmin-1; n-6).
Thromboxane B e release from sensitized unchallenged lungs (14.5 -k 1.6 ng min-1., n 4) was not affected by 100nM infusion AF-2 (13.4-k 1.1ngmin-l" n=4) Antiflammin-2 infusion (100 nM) did not modify either the peak response or the time course of the antigen-induced histamine release from sensitized lungs (Fig. 2B) 23 Another aspect which could affect the biological activity of the peptide might be its oxidation possibly occurring during the experimental procedures. In fact it has been suggested that AF-2 might be inactivated by spontaneous oxidation of its methionine residue in the position 3 
